Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, announced it will host an investor conference call on Feb. 19, 2026, at 3 p.m. Central Time. The call will provide an overview of the company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD(TM) and PrecisionCHD(TM).
The scheduled call comes as Cardio Diagnostics continues to advance its proprietary AI-driven Integrated Genetic-Epigenetic Engine, which forms the core technology behind its clinical tests. The company plans to discuss recent clinical data, reimbursement progress, and strategic growth initiatives during the session. For investors and stakeholders, this call offers a timely opportunity to gain insights into the company's operational milestones and future direction.
Cardio Diagnostics focuses on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. Its tests leverage a combination of genetic and epigenetic markers to assess coronary heart disease risk, a leading cause of mortality worldwide. The upcoming update is particularly significant as the company navigates the competitive landscape of precision medicine, where reimbursement and clinical adoption are key drivers of success.
The full press release detailing the conference call can be accessed at https://ibn.fm/3xwFk. For more information about Cardio Diagnostics and its technology, visit the company's website at https://cdio.ai/.
This announcement underscores the growing importance of precision diagnostics in cardiovascular medicine. As healthcare shifts toward personalized treatments, Cardio Diagnostics' AI-based approach could play a pivotal role in early risk identification and intervention. The investor call will likely provide clarity on the company's path to broader market penetration and financial sustainability.
BioMedWire, a specialized communications platform for the biotech and life sciences sectors, also noted the event. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which delivers wire solutions, editorial syndication, and corporate communications services. For more details about BioMedWire, visit https://www.BioMedWire.com.
Cardio Diagnostics' focus on integrating artificial intelligence with genetic and epigenetic data positions it at the forefront of cardiovascular innovation. The Feb. 19 call will be a key moment for investors to assess the company's progress and the potential impact of its tests on patient care.
